89Zr标记自然杀伤细胞的体内PET成像及治疗性抗体的调节效应
研究用[89Zr]Zr-oxine标记体外扩增的人自然杀伤(NK)细胞,在HER2阳性HCC1954乳腺癌原位小鼠模型中行PET/CT追踪7天,并比较曲妥珠单抗治疗与假治疗的影响。标记后NK细胞保持表型与功能,体内主要蓄积于肝脾,并可迁移至HER2阳性肿瘤;曲妥珠单抗治疗与注射后第1天和第3天89Zr-NK细胞信号升高相关。
要点
- 89Zr-NK细胞在体外保持CD56、CD16表达及活力、迁移、脱颗粒和ADCC功能。
- 体内PET/CT显示89Zr-NK细胞主要蓄积于肝脾,并可迁移至HER2阳性肿瘤。
- 曲妥珠单抗治疗与注射后第1天和第3天89Zr-NK细胞信号升高相关。
核心结论
- 体外89Zr-NK细胞保持关键细胞与细胞毒功能,体内可迁移至HER2阳性肿瘤,曲妥珠单抗治疗与89Zr-NK浸润增强相关。
- 本研究证明用PET成像89Zr-NK细胞浸润实体瘤具有可行性。
研究设计与样本
- 人NK细胞来自健康供者,经体外扩增后用[89Zr]Zr-oxine标记。
- 体外比较标记(89Zr-NK)与未标记NK细胞的表型标志、活力、增殖、迁移、脱颗粒和ADCC行为。
- 雌性小鼠荷原位人乳腺癌HCC1954肿瘤,给予89Zr-NK细胞并联合曲妥珠单抗治疗或假治疗,行PET/CT扫描7天。
- 用流式细胞术和γ计数分析肝脾组织中89Zr-NK细胞的存在。
主要发现
- 89Zr细胞标记产率为42.2%±8.0%。
- 在平均比活度16.7±4.7 kBq/10^6细胞下,89Zr-NK细胞保持CD56和CD16表达、活力、迁移、脱颗粒及ADCC能力等表型与功能特征。
- 体内PET/CT研究显示89Zr-NK细胞主要蓄积于肝和脾。
- 肝脾组织离体分析显示给予的人89Zr-NK细胞在体内保留放射性,89Zr未转移至小鼠软组织细胞。
- 89Zr-NK细胞在有无曲妥珠单抗治疗时均迁移至HER2阳性肿瘤;曲妥珠单抗治疗与注射后第1天和第3天89Zr-NK细胞信号增加相关。
关键数值与推荐
- 89Zr细胞标记产率为42.2%±8.0%。
- 平均比活度为16.7±4.7 kBq/10^6细胞。
- PET/CT扫描时间为7天。
- 曲妥珠单抗治疗与注射后第1天和第3天89Zr-NK细胞信号增加相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Natural killer (NK) cells can kill cancer cells via antibody-dependent cell-mediated cytotoxicity (ADCC): a tumor-associated IgG antibody binds to the Fcγ receptor CD16 on NK cells via the antibody Fc region and activates the cytotoxic functions of the NK cell. Here, we used PET imaging to assess NK cell migration to human epidermal growth factor receptor 2 (HER2)-positive HCC1954 breast tumors, examining the influence of HER2-targeted trastuzumab antibody treatment on NK cell tumor accumulation. Methods: Human NK cells from healthy donors were expanded ex vivo and labeled with [89Zr]Zr-oxine. In vitro experiments compared the phenotypic markers, viability, proliferation, migration, degranulation, and ADCC behaviors of both labeled (89Zr-NK) and unlabeled NK cells. Female mice bearing orthotopic human breast HCC1954 tumors were administered 89Zr-NK cells alongside trastuzumab treatment or a sham treatment and then scanned using PET/CT imaging over 7 d. Flow cytometry and γ-counting were used to analyze the presence of 89Zr-NK cells in liver and spleen tissues. Results: 89Zr cell radiolabeling yields measured 42.2% ± 8.0%. At an average specific activity of 16.7 ± 4.7 kBq/106 cells, 89Zr-NK cells retained phenotypic and functional characteristics including CD56 and CD16 expression, viability, migration, degranulation, and ADCC capabilities. In vivo PET/CT studies indicated predominant accumulation of 89Zr-NK cells in the liver and spleen. Ex vivo analyses of liver and spleen tissues indicated that the administered human 89Zr-NK cells retained their radioactivity in vivo and that 89Zr did not transfer to cells of murine soft tissues, thus validating this 89Zr PET method for NK cell tracking. Notably, 89Zr-NK cells migrated to HER2-positive tumors, both with and without trastuzumab treatment. Trastuzumab treatment was associated with an increased 89Zr-NK cell signal at days 1 and 3 after injection. Conclusion: In vitro, 89Zr-NK cells maintained key cellular and cytotoxic functions. In vivo, 89Zr-NK cells trafficked to HER2-postive tumors, with trastuzumab treatment correlating with enhanced 89Zr-NK infiltration. This study demonstrates the feasibility of using PET to image 89Zr-NK cell infiltration into solid tumors.
引用
- Pham TT, Chenoweth A, Patel N, et al. In Vivo PET Imaging of 89Zr-Labeled Natural Killer Cells and the Modulating Effects of a Therapeutic Antibody. J Nucl Med. 2024. PMID: 38844362. doi:10.2967/jnumed.124.267876
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。